NCT07071506 New Methods for Evaluating Preventive Migraine Treatment
| NCT ID | NCT07071506 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Aarhus |
| Condition | Migraine |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-06-19 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-06-19 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, balanced placebo design, patients with chronic migraine will receive four treatment conditions in a randomized order.
Eligibility Criteria
Inclusion Criteria: 1. Adults (18-65 years) 2. ≥ 1-year history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria 3. Known chronic migraine (headache occurring ≥ 15 days per month for \> 3 months, which on at least 8 days per month has the features of migraine headache) diagnosed before age 65 4. Eligibility for preventive migraine treatment 5. Ability to speak and read Danish Exclusion Criteria: 1. Use of onabotulinumtoxinA as preventive migraine treatment during the 4 months before inclusion 2. Use of other preventive migraine treatment except CGRP antagonists (However, participants are allowed to be on two stable preventive medication (antidepressant, calcium channel blockers, beta blockers or antiepileptic)- 2 months prior to inclusion until end of study), devices for migraine prevention such as transcranial magnetic stimulation and use of nerve blocks 3 months prior to inclusion 3. Use of opioid or barbiturate medications in the last four weeks before inclusion 4. Secondary headache disorders including medication overuse headache 5. Severe psychiatric, vascular disease, or known liver disease 6. Alcohol abuse or substance abuse 7. Current or planned pregnancy and lactation
Contact & Investigator
Lene Vase, MSc, PhD, DMSc
PRINCIPAL INVESTIGATOR
Dept. of Psychology and Behavioural Sciences, Aarhus University, Aarhus, Denmark
Frequently Asked Questions
Who can join the NCT07071506 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Migraine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07071506 currently recruiting?
Yes, NCT07071506 is actively recruiting participants. Contact the research team at lunde@psy.au.dk for enrollment information.
Where is the NCT07071506 trial being conducted?
This trial is being conducted at Aarhus C, Denmark, Aarhus N, Denmark.
Who is sponsoring the NCT07071506 clinical trial?
NCT07071506 is sponsored by University of Aarhus. The principal investigator is Lene Vase, MSc, PhD, DMSc at Dept. of Psychology and Behavioural Sciences, Aarhus University, Aarhus, Denmark. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.